Alvotech reports positive topline results for Xolair biosimilar study

DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme

Celltrion's OMLYCLO receives US FDA approval

Kenox Pharmaceuticals partners with Lactiga US

Health Canada approves ALK's ACARIZAX for young children with dust mite allergy

Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL

CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema

NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS

European Commission approves Palforzia for toddlers with peanut allergy

Eli Lilly and Co receives approval from FDA for Zepbound

CSL gains EMA backing for Garadacimab as HAE prophylactic treatment

Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)

Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial

CBC Group acquires UCB's mature neurology and allergy business in China

Allergy Therapeutics begins Phase III trial for grass allergy treatment in children